9 citations
,
February 2022 in “European Journal of Pharmaceutics and Biopharmaceutics” This study suggests that a nanostructured lipid carrier formulation delivering minoxidil and latanoprost may enhance effectiveness and tolerability in treating alopecia by targeting hair follicles.
January 2018 in “Surgical and Cosmetic Dermatology” This study found that treatments with 5% minoxidil, with or without latanoprost, were effective in controlling hair loss and increasing hair strand count in patients with telogen effluvium or androgenic alopecia.
January 2021 in “Social Science Research Network” This study suggests that a nanostructured lipid carrier formulation of minoxidil and latanoprost may effectively target hair follicles and enhance drug penetration for alopecia treatment.
8 citations
,
October 2022 in “Dermatologic Therapy” In this study, the addition of topical latanoprost to betamethasone treatment improved the therapeutic efficacy for patients with patchy alopecia areata, showing more significant hair regrowth compared to minoxidil alone and enhanced outcomes without adverse effects.
July 2024 in “International Journal of Medical Arts” In this study, both topical minoxidil and latanoprost were found to improve dermoscopic features of alopecia areata, with latanoprost showing superior effectiveness; minor side effects included erythema and itching.